

Index

A

- Agenaes syndrome, 114
- Abnormal placental vascularization
 - and pregnancy complications, 88–89
- Adult-onset Lhermitte-Duclos disease (LDD), 119
- Angioendotheliomatosis, 3
- Angiogenesis, 84–88
 - embryonic body axis, 83–84
 - placental development
 - (see Placental development)
- Angiokeratomas, 107
- Angiosarcoma
 - clinical features, 29
 - histology, 29–30
 - pathogenesis, 31–32
- Arteriovenous malformations (AVMs), 10, 33, 90
 - clinical features, 44
 - histology, 44–46
 - pathogenesis, 46–48
 - RASA1 mutations, 105
- Artery vs. vein (A/V) specification
 - mechanisms
 - angioblasts, 81
 - FoxC1 and FoxC2 family, 82
 - ligand ephrin-B2 (efnb2), 81
 - MAPK and PI3K pathways, 82
 - primitive vessels, 81
 - Shh-VEGF-Notch pathway, 82
 - VEGF overexpression, 82
- AVMs. *See* Arteriovenous malformations (AVMs)

B

- Bannayan-Riley-Ruvalcaba syndrome (BRRS), 69, 70, 117–119
- Beckwith-Wiedemann syndrome, 68–69
- Blue rubber bleb nevus syndrome (BRBNS), 39
- BRRS. *See* Bannayan-Riley-Ruvalcaba syndrome (BRRS)

C

- Capillary hemangiomas, 2, 101
- Capillary malformation-arteriovenous malformation (CM-AVM), 70
- Capillary malformations (CMs), 33–36, 67
 - endothelial antigens, 105
 - “port-wine stain”, 105
 - slow-flow vascular malformations, 101
- CCM1/KRIT1 protein, 109
- CCM2/Malcaavernin, 109
- Cerebral cavernous malformations (CCMs), 109
 - clinical diagnosis, 108
 - familial vascular malformations, 107
 - genetic counseling, 110
 - hemorrhage and neurologic deficits, 108
 - molecular diagnosis, 108
 - molecular pathogenesis
 - CCM1/KRIT1, 109
 - CCM2/Malcaavernin, 109
 - CCM3/PDCD10, 109
 - molecular testing, 109–110
 - serial MRIs and brain biopsies, 108
- Chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII), 82

- Circulatory system, 77–79
 angiogenesis (*see* Angiogenesis)
 blood and lymphatic vessels, 77
 embryonic programs, 78
 hemangioblast (*see* Hemangioblast)
 lymphatic vessel specification,
 82–83
 organogenesis, 77
 vascular lineage (*see* Vascular lineage)
 vasculogenesis (*see* Vasculogenesis)
- Composite hemangioendothelioma (CHE)
 clinical features, 25–26
 histology, 26
 pathogenesis, 26
- Congenital lipomatous asymmetric
 overgrowth, vascular malformation,
 epidermal nevus and skeletal
 anomalies (CLOVES) syndrome,
 52, 63–65
- Congenital nonprogressive hemangioma
 clinical features, 9–10
 histology, 10–13
 pathogenesis, 13
- Corticosteroids
 systemic therapy, 134–136
 topical therapy, 133
- COUP-TFII. *See* Chicken ovalbumin upstream
 promoter-transcription factor II
 (COUP-TFII)
- Cowden syndrome (CS), 69, 70, 117–119
- CS. *See* Cowden syndrome (CS)
- Cutis marmorata telangiectatica congenita
 (CMTC), 68
- D**
- Dabska tumors, 23, 25
- DLAVs. *See* Dorsal longitudinal anastomotic
 vessel (DLAVs)
- Dorsal longitudinal anastomotic vessel
 (DLAVs), 83
- E**
- Embryo development, 81–84
 angiogenesis (*see* Angiogenesis)
 A/V specification mechanisms (*see* Artery
 vs. vein (A/V) specification
 mechanisms)
 vasculogenesis (*see* Vasculogenesis)
- Epithelioid angiosarcomas, 27, 29–31
- Epithelioid hemangioendothelioma (EHE)
 clinical features, 26–27
 histology, 27–28
 pathogenesis, 28–29
- Epithelioid hemangioma, 18
 clinical features, 16–17
 histology, 17–18
 pathogenesis, 18
- F**
- FAP68 function, 43
- FDH. *See* Focal dermal hypoplasia (FDH)
- FFPE. *See* Formalin-fixed paraffin-embedded
 (FFPE)
- Focal dermal hypoplasia (FDH), 107
- Formalin-fixed paraffin-embedded (FFPE), 121
- G**
- Generalized lymphatic anomaly (GLA),
 49, 50
- Genetic counseling, 110, 119–120
- Germline PTEN mutations, 33–34, 48
- Germline RASA1 mutations, 33–34
- Glomangioma, 41
- Glomeruloid hemangioma, 3
- Glomulin mutations, 112–113
- Glomuvenous malformations (GVMs)
 categories, 41
 clinical features, 42
 diagnosis, 112
 glomangioma, 41
 glomulin mutations, 112–113
 hereditary vascular malformations, 112
 histology, 42
 molecular genetic testing, 113
 pathogenesis, 42–43
- Glucose transporter protein-1 (GLUT-1), 6,
 8–9
- Gorham–Stout disease, 50, 52
- GVMs. *See* Glomuvenous malformation
 (GVM)
- H**
- HBT. *See* Hereditary benign telangiectasias
 (HBT)
- Hemangioblast
 description, 79
 ESC-derived EB model system, 79
 genes, 79
 single-cell-resolution fate maps, 79
- Hemangioma
 capillary, 2
 congenital nonprogressive, 3
 generic use of, 1, 2
 infantile (*see* Infantile hemangiomas (IHs))
 vascular tumors, 89

Hennekam syndrome, 114
 Hepatic hemangioma
 clinical features, 13–14
 histology, 14–15
 Hepatic IH, 13
 Hepatic RICH, 13, 14
 Hereditary benign telangiectasias
 (HBT), 106
 Hereditary hemorrhagic telangiectasia (HHT),
 46, 48, 106
 HHT. *See* Hereditary hemorrhagic telangiectasia
 (HHT)
 Hobnail hemangioma, 16
 clinical features, 15
 histology, 15–16
 pathogenesis, 16
 Hypotrichosis lymphedema telangiectasia
 (HLT) syndrome, 114

I

IHs. *See* Infantile hemangiomas (IHs)
 Infantile hemangiomas (IHs)
 clinical features, 4, 5, 131
 complications, 4, 131
 histology, 5–9
 pathogenesis, 9
 PHACES syndrome, 4, 114, 137
 systemic therapy (*see* Systemic therapy)
 therapeutic options, 4–5, 115,
 131–139
 topical therapy (*see* Topical therapy)
 ulceration (*see* Ulceration)
 International Society for the Study of Vascular
 Anomalies (ISSVA)
 classification, 1–3, 19
 Intersomitic vessels (ISVs), 78, 83

K

Kaposiform hemangioendothelioma (KHE)
 clinical features, 19–20
 histology, 20–21
 pathogenesis, 21
 Kasabach-Merritt phenomenon (KMP)
 clinical presentation, 139–140
 description, 19, 139
 platelets and clotting factors, 139
 treatment, 140–141
 Klippel-Trenaunay syndrome (KTS), 19, 31,
 33–34, 49, 67, 90, 114
 KMP. *See* Kasabach-Merritt phenomenon
 (KMP)
 KTS. *See* Klippel-Trenaunay syndrome
 (KTS).

L

Laboratory-developed tests (LDTs), 120
 Lateral plate mesoderm (LPM), 78–81, 91
 LMs. *See* Lymphatic malformations (LMs)
 LPM. *See* Lateral plate mesoderm (LPM)
 Lymphangiomatosis, 49
 Lymphatic malformations (LMs), 90, 113
 clinical features, 48, 49
 histology, 49, 51
 pathogenesis, 52
 targetoid, 25
 Lymphatic-venous malformations
 clinical features, 49
 histology, 51
 pathogenesis, 52
 Lymphatic vessel specification, 82–83
 Lymphedemas, 114

M

Macrocephaly-Capillary malformation
 (M-CM) syndrome, 68
 Maffucci syndrome, 19, 26, 90, 116
 MAPK. *See* Mitogen-activated protein kinase
 (MAPK)
 Masson's vegetant intravascular
 hemangioendothelioma, 37
 Megalencephaly-capillary malformation
 (MCAP), 68
 Microvenular hemangioma, 3
 Mitogen-activated protein kinase (MAPK), 36,
 82, 109, 117
 Multifocal lymphangioendotheliomatosis with
 thrombocytopenia (MLT)
 clinical features, 22
 histology, 22
 pathogenesis, 22

N

Non-involuting congenital hemangioma
 (NICH), 3, 9, 10, 13, 114
 Nonne-Milroy syndrome, 114

O

Osler-Rendu-Weber syndrome, 48

P

Papillary intralymphatic angioendothelioma
 (PILA)
 clinical features, 23
 histology, 23–24
 pathogenesis, 24

- Parkes–Weber syndrome (PKWS), 47, 70–71
- Partially involuting congenital hemangioma (PICH), 3, 10, 13
- PDL. *See* Pulsed dye laser (PDL)
- Phosphatase and tensin homolog (PTEN) protein
 - clinical molecular testing, 118
 - deletions and duplications, 118
 - germline mutations, 117
 - non-PTEN gene mutations, 118–119
 - sequence analysis of, 118
 - testing strategies, 119
 - tumor suppressor protein, 117
- Phosphoinositide-3-kinase (PI3K)
 - pathways, 82
- PHTS. *See* PTEN hamartoma tumor syndrome (PHTS)
- PI3K. *See* Phosphoinositide-3-kinase (PI3K)
 - pathways
- PI3K-AKT pathway, 71
- Placental development
 - angiogenic processes, 84
 - fetoplacental vascularization, 88
 - growth factors, 87
 - murine placenta, 84, 85
 - PHACES syndrome, 4, 114, 137
 - TGCs, 87
 - trophoblast cells, 84
 - trophoblast differentiation and pseudovasculogenesis, 86
 - uterine angiogenesis and vascular remodeling, 85
 - uterine neovascularization, 86
- Port-wine stain (PWS), 31, 33
 - clinical features, 34
 - GNAQ gene, 34
 - histology, 35
 - pathogenesis, 35–36
 - Sturge–Weber syndrome, 33
- Programmed cell death protein 10 (PDCD10) gene, 109
- Progressive patchy capillary malformations, 107
- Propranolol, 4–5, 136–137
- Proteus syndrome, 65–67
- PS. *See* PTEN-related Proteus syndrome (PS)
- PTEN. *See* Phosphatase and tensin homolog (PTEN) protein
- PTEN hamartoma tumor syndromes (PHTS), 45, 46, 69–70, 116
 - AVMs, 117
 - CS, BRRS, PS and proteus-like syndrome, 117
 - vascular anomalies, 116, 117
- PTEN*-related Proteus syndrome (PS), 117
- Pulsed dye laser (PDL), 138
- Pyogenic granulomas, 3, 13
- R**
- Rapidly involuting congenital hemangioma (RICH), 9, 10, 13, 14
- Recombinant interferon alpha (IFN- α), 138
- Rendu-Osler-Weber syndrome. *See* Hereditary hemorrhagic telangiectasia (HHT)
- Retiform hemangioendothelioma (RHE)
 - clinical features, 24
 - histology, 25
 - pathogenesis, 25
- S**
- Segmental overgrowth, lipomatosis, arteriovenous malformation and epidermal nevus (SOLAMEN) syndrome, 69
- Somatic PIK3CA mutations, 34
- Sonic hedgehog (Shh)-VEGF-Notch pathway, 82
- Spindle cell hemangioma (SCH)
 - clinical features, 18
 - histology, 18
 - pathogenesis, 19
- Sturge–Weber syndrome (SWS), 33
- Surgical excision, 138
- Systemic therapy
 - corticosteroids, 134–136
 - interferon, 138
 - pharmacogenetics and treatment, 116
 - propranolol, 136–137
 - vincristine, 137–138
- T**
- Targetoid hemosiderotic lymphatic malformation, 16
- TGCs. *See* Trophoblast giant cells (TGCs)
- TIE2 mutation, 38
- Timolol, 134
- Topical imiquimod, 133, 134
- Topical therapy
 - corticosteroids, 133
 - imiquimod, 133–134
 - timolol, 134
- Trophoblast giant cells (TGCs), 87
- Tufted angioma (TA)
 - clinical features, 19–20
 - histology, 20–21
 - pathogenesis, 21

U

Ulceration

- description, 132
- gentle debridement, crust, 133
- nonadherent dressings, 133
- pulsed dye laser, 133

V

Vascular anomalies, 1, 89

Vascular lineage

- ectoderm, endoderm and mesoderm, 78
- gene targeting experiments, 79
- hemangioblast, 79
- vascular ECs, 78

Vascular malformations, 32

- clinical features, 34, 37, 39–40, 42, 44, 48–49
- histology, 32, 35, 37, 40, 42, 44–46
- ISSVA-sanctioned classification, 33
- molecular diagnosis of, 101–104
- pathogenetic mechanisms, 35–36, 38–39, 41–43, 46–48, 90–91

Vascular overgrowth

- Beckwith-Wiedemann syndrome, 68–69
- CLOVES syndrome, 63–65
- CM-AVM, 70

CMTC, 68

etiology, 71–72

KTS, 67

MCAP, 68

PHTS, 69–70

PKWS, 70–71

proteus syndrome, 65–67

Vascular tumors, 3–32, 114–116

Vasculogenesis, 84–88

angioblast, 80

EC-derived secreted factor
Egfl-7, 80

Etsrp+ angioblast cell development, zebra
fish embryo, 80, 81

etsrp cells, 80

in placental development

(*see* Placental development)

Venous malformations

- clinical features, 37
- histology, 37–38
- pathogenesis, 38–39

Verrucous hemangioma, 34

Verrucous venulocapillary malformation

- clinical features, 39–40
- histology, 40–41
- ISSVA classification, 39
- pathogenesis, 41